Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. develops late clinical-stage biopharmaceutical programs based on nose-to-brain neurocircuitry and intranasal pherine product candidates. Company news centers on fasedienol nasal spray for the acute treatment of social anxiety disorder, including PALISADE Phase 3 study updates, and refisolone nasal spray for vasomotor symptoms due to menopause.
Recurring updates also cover FDA and IND communications, clinical data from psychiatric and neurological programs, fiscal results, cash-management actions, executive and board changes, and healthcare investor conference presentations. The company’s pipeline is described around investigational intranasal candidates for indications that include social anxiety disorder, major depressive disorder, and menopausal hot flashes.
VistaGen Therapeutics (Nasdaq: VTGN) announced that underwriters of its public offering exercised their over-allotment option, bringing additional gross proceeds of approximately $1.79 million. Overall, the offering totaled $14.29 million with 17,868,250 shares issued. The funds will support the development of CNS pipeline programs, general research, and working capital. Maxim Group LLC managed the offering, which was conducted under an effective shelf registration statement with the SEC.
VistaGen Therapeutics, Inc. (Nasdaq: VTGN) has closed an underwritten public offering of 15,625,000 shares at $0.80 per share, generating $12.5 million in gross proceeds. The proceeds will support the development of CNS pipeline programs, R&D, and general corporate purposes. An option for underwriters to purchase up to an additional 2,343,750 shares within 45 days is also granted. The offering was conducted under an effective shelf registration statement.
VistaGen Therapeutics (NASDAQ: VTGN) received a $5 million non-dilutive upfront license payment from EverInsight Therapeutics for the development of PH94B, a nasal spray targeting anxiety-related disorders. This collaboration focuses on commercializing PH94B in key Asian markets, including Greater China and Southeast Asia.
VistaGen is eligible for milestone payments and royalties on future sales. The FDA has granted Fast Track designation for PH94B's Phase 3 development as a treatment for social anxiety disorder (SAD), marking it as a potential breakthrough in non-addictive anxiety treatment.
VistaGen Therapeutics, Inc. (Nasdaq: VTGN) announced the pricing of a public offering of 15,625,000 shares at $0.80 per share, aiming to raise gross proceeds of approximately $12.5 million. The underwriter has a 45-day option to purchase an additional 2,343,750 shares. The funds will support the development of its central nervous system (CNS) pipeline programs as well as general research and development. This offering is part of an effective shelf registration statement filed with the SEC.
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) has announced an underwritten public offering of common stock, subject to market conditions. The company aims to utilize the proceeds for the continued development of its central nervous system (CNS) pipeline, general research, working capital, and corporate purposes. Maxim Group LLC serves as the sole book-running manager for the offering. This offering is made under an effective shelf registration statement, and a preliminary prospectus supplement will be filed with the SEC.
VistaGen Therapeutics (VTGN) reported its financial results for the fiscal year ending March 31, 2020. The company experienced a decrease in net loss to $22 million from $25.7 million the previous year, primarily due to lower research and development expenses. VistaGen's cash position stood at $1.4 million, with subsequent proceeds of $3 million after fiscal year-end. The strategic collaboration with EverInsight aims to develop PH94B, a nasal spray for anxiety disorders, with potential payments up to $177 million, enhancing the company's pipeline targeting mental health care.
VistaGen Therapeutics (NASDAQ: VTGN) has entered a strategic licensing agreement with EverInsight Therapeutics for the development and commercialization of PH94B, a novel neurosteroid for anxiety disorders, in Greater China, South Korea, and Southeast Asia. VistaGen will receive a $5 million upfront payment and potential milestone payments of up to $172 million. The collaboration aims to advance Phase 3 clinical development for PH94B, which has Fast Track designation from the FDA for social anxiety disorder. VistaGen retains rights outside this territory.